Silence Therapeutics Business Summary

Silence Therapeutics plc (SLN) is a clinical-stage biotechnology company that generates revenue through a hybrid model of proprietary drug development and high-value strategic collaborations. The company leverages its proprietary mRNAi GOLD™ (GalNAc Oligonucleotide Discovery) platform to create short-interfering RNA (siRNA) therapies designed to silence disease-causing genes in the liver. Its primary business segments are focused on cardiovascular disease, hematology, and rare diseases, with lead candidates Zerlasiran (targeting Lipoprotein(a)) and Divesiran (targeting TMPRSS6) driving its clinical pipeline. Revenue is derived from upfront payments, R&D funding, and milestone achievements from partners such as AstraZeneca and Hansoh Pharma. Silence competes directly with RNA-based therapy leaders Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals, positioning itself as a specialized, platform-centric player with a high-density focus on liver-targeted precision medicine. The leadership team is currently headed by Interim CEO and Chairman Iain Ross, a life sciences veteran with over 40 years of experience at Sandoz and Hoffmann-La Roche. Key executives include Executive VP and CFO Rhonda Hellums, who brings 25 years of corporate finance expertise from Genzyme and 3M+KCI, and Chief Research and Development Officer Dr. Steven Romano, a former Pfizer executive. The scientific core is directed by CSO Dr. Marie Wikström Lindholm, an oligonucleotide specialist, and Chief Technical Operations Officer J.P. Gabriel, formerly of Genentech. Originally founded in 1994 as Atugen AG by scientists from the Max Planck Institute, the company is supported by a sophisticated investor base including Great Point Partners, Adage Capital Management, and Frazier Healthcare Partners. The board features seasoned directors such as Tim McInerney and Dave Lemus, ensuring robust governance and deep industry pedigree.